The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.
An article from
Dive Brief
The Swiss pharmaceutical giant told patient groups tominersen didn’t delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.
Published July 9, 2026
Roche has ended clinical development of tominersen and RG6496, two drugs it's been developing for Huntington's disease.
The decision comes after tominersen did no better than placebo in a Phase 2 trial with patients in the earliest stages of the…
The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a…
Merck ends a Phase 2 Alzheimer's trial for MK-1167, partnered with Neuphoria Therapeutics, after the drug missed efficacy…
Roche’s lung cancer drug candidate divarasib has beaten marketed drugs from Amgen and Bristol Myers Squibb in a head-to-head…
(Bloomberg) -- Roche Holding AG’s experimental lung cancer pill outperformed two approved medicines in a late-stage study,…
The FDA has reversed its opposition to a closely watched experimental treatment for Huntington’s disease, clearing a path for its…
